Tenaya Therapeutics Files 8-K Report
Ticker: TNYA · Form: 8-K · Filed: Dec 11, 2025
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Tenaya Therapeutics filed an 8-K on 12/11/25. Details TBD.
AI Summary
On December 11, 2025, Tenaya Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. No specific financial figures or material events beyond the filing itself were detailed in the provided text.
Why It Matters
This 8-K filing indicates that Tenaya Therapeutics, Inc. has submitted a report to the SEC, which may contain updates on corporate events or financial information.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific material events or financial data that would indicate a change in risk.
Key Players & Entities
- Tenaya Therapeutics, Inc. (company) — Registrant
- December 11, 2025 (date) — Date of earliest event reported
- 171 Oyster Point Boulevard, Suite 500 (address) — Principal executive offices
- South San Francisco, CA 94080 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing by Tenaya Therapeutics, Inc.?
The filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, covering Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on December 11, 2025.
What is the principal executive office address for Tenaya Therapeutics, Inc.?
The address is 171 Oyster Point Boulevard, Suite 500, South San Francisco, CA 94080.
What is the SEC file number for Tenaya Therapeutics, Inc.?
The SEC file number is 001-40656.
What is the SIC code for Tenaya Therapeutics, Inc.?
The Standard Industrial Classification code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 1,751 words · 7 min read · ~6 pages · Grade level 13.6 · Accepted 2025-12-11 16:11:50
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share TNYA Nasdaq Global Select
Filing Documents
- d68368d8k.htm (8-K) — 38KB
- d68368dex991.htm (EX-99.1) — 14KB
- d68368dex992.htm (EX-99.2) — 31KB
- g68368g08g85.jpg (GRAPHIC) — 7KB
- g68368g1211225610211.jpg (GRAPHIC) — 3KB
- 0001193125-25-315951.txt ( ) — 233KB
- tnya-20251211.xsd (EX-101.SCH) — 3KB
- tnya-20251211_lab.xml (EX-101.LAB) — 18KB
- tnya-20251211_pre.xml (EX-101.PRE) — 11KB
- d68368d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this report that are not purely historical are forward-looking statements. Words such as "will," "anticipated," "believe," "look forward," "potential," and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, among other things, the planned timing to resume dosing for MyPEAK-1; the planned timing to report additional data from MyPEAK-1; the planned timing to report additional data from RIDGE-1; the clinical, therapeutic and commercial potential of, and expectations regarding TN-401; the value of additional RIDGE-1 data to inform the potential of TN-401; the inferences regarding PKP2 protein and mRNA expression; and statements regarding the continued development TN-401 and TN-401 clinical outcomes, which may materially change as patient enrollment continues or more patient data become available. The forward-looking statements contained herein are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: availability of RIDGE-1 data at the referenced time; the timing and progress of RIDGE-1; the potential failure of TN-401 to demonstrate safety and/or efficacy in clinical testing; the potential for any RIDGE-1 clinical trial results to differ from preclinical, interim, preliminary or expected results; the Company's ability to enroll and maintain patients in clinical trials, including RIDGE-1; risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeut
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description. 99.1 Press Release dated December 11, 2025. 99.2 Press Release dated December 11, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TENAYA THERAPEUTICS, INC. By: /s/ Jennifer Drimmer Rokovich Jennifer Drimmer Rokovich General Counsel and Secretary Date: December 11, 2025